This 74-acre fully integrated R&D and GMP manufacturing campus currently includes 2 R&D center, 15 plants. Changzhou is about 1-hour driving distance (75 km) to Wuxi city (drug product site) which enables seamless collaborations between API teams and formulation teams for efficient, flexible, and high-quality solutions to global pharma and biotech customers.
Changzhou site is a fully integrated R&D and manufacturing campus providing a unique one-site solution for APIs and advanced intermediates, including small molecule, HPAPI, oligonucleotide, peptide, and related synthetic conjugates, through preclinical and clinical development to global commercial launch.
Changzhou site has successfully passed inspections by US FDA, China NMPA, Japan PMDA and South Korea MFDS multiple times since 2018.
